An Open-label, Multi-center Phase I/II Study to Assess the Safety and the Efficacy of SMART101 After Haploidentical Peripheral Blood Stem Transplantation With Post-transplant Cyclophosphamide in Subjects With Hematological Malignancies
Latest Information Update: 10 Apr 2025
At a glance
- Drugs SMART 101 (Primary)
- Indications Acute myeloid leukaemia; Haematological malignancies; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms ReSET-02
- Sponsors Smart Immune
Most Recent Events
- 01 Apr 2025 According to Smart Immune media release, The company is still working to produce additional data from our ReSET-02 clinical trial in adult acute leukemia patients, albeit more slowly.
- 23 Oct 2024 According to Smart Immune media release, company announced that the recommended dose for its lead candidate, SMART101, has been established following the completion of the ReSET-02 trial phase 1 dose escalation segment. Phase II PoC Randomized segment is starting.
- 02 May 2024 According to a Smart Immune media release, the company announced the treatment of the first patient in the third and final dose cohort of the dose-escalation stage in its ReSET-02 trial.